Relevance of non-albumin colloids in intensive care medicine

Best Practice and Research: Clinical Anaesthesiology

Volumn 23, Issue 2, 2009, Pages 193-212

  Ertmer, Christian ^a   Rehberg, Sebastian ^a   Van Aken, Hugo ^a   Westphal, Martin ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

colloids; dextrans; fluid therapy; gelatin; hydroxyethyl starch; intensive care medicine; sepsis

Indexed keywords

DEXTRAN; DEXTRAN 40; DEXTRAN 70; EXPAFUSIN; GELAFUSIN; GELATIN; GELATIN SUCCINATE; HEMOHES; HETASTARCH; HUMAN SERUM ALBUMIN; LONGASTERIL 70; OXYPOLYGELATIN; PLASMA SUBSTITUTE; POLYGELINE; POVIDONE; RHEOHES; RINGER ACETATE; RINGER LACTATE SOLUTION; TETRASPAN; UNCLASSIFIED DRUG; VENOFUNDIN; VITAHES; VOLULYTE;

ANAPHYLAXIS; CLINICAL TRIAL; COLLOID; CRITICALLY ILL PATIENT; CRYSTALLOID; DISTRIBUTION VOLUME; DIURESIS; DRUG CLEARANCE; DRUG STRUCTURE; FLUID RESUSCITATION; HALF LIFE TIME; HEMOSTASIS; HUMAN; HYPOVOLEMIA; INTENSIVE CARE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY INJURY; LIVER TOXICITY; MOLECULAR WEIGHT; MORTALITY; NONHUMAN; ONCOTIC PRESSURE; PHARMACODYNAMICS; PLASMA VISCOSITY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SIDE EFFECT; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

COLLOIDS; DEXTRANS; FLUID THERAPY; GELATIN; HETASTARCH; HUMANS; INTENSIVE CARE; KIDNEY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 66449099093     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpa.2008.11.001     Document Type: Review

References (109)

1. Schadt J.C., and Ludbrook J. Hemodynamic and neurohumoral responses to acute hypovolemia in conscious mammals. The American Journal of Physiology 260 (1991) H305-H318
2. Vincent J.L., and Weil M.H. Fluid challenge revisited. Critical Care Medicine 34 (2006) 1333-1337
3. Hinder F., Stubbe H.D., Van Aken H., et al. Early multiple organ failure after recurrent endotoxemia in the presence of vasoconstrictor-masked hypovolemia. Critical Care Medicine 31 (2003) 903-909
4. Moller A.M., Pedersen T., Svendsen P.E., and Engquist A. Perioperative risk factors in elective pneumonectomy: the impact of excess fluid balance. European Journal of Anaesthesiology 19 (2002) 57-62
5. Schuller D., Mitchell J.P., Calandrino F.S., and Schuster D.P. Fluid balance during pulmonary edema. Is fluid gain a marker or a cause of poor outcome?. Chest 100 (1991) 1068-1075
6. Simmons R.S., Berdine G.G., Seidenfeld J.J., et al. Fluid balance and the adult respiratory distress syndrome. The American Review of Respiratory Disease 135 (1987) 924-929
7. Rehm M., Haller M., Orth V., et al. Changes in blood volume and hematocrit during acute preoperative volume loading with 5% albumin or 6% hetastarch solutions in patients before radical hysterectomy. Anesthesiology 95 (2001) 849-856
8. Rehm M., Zahler S., Lotsch M., et al. Endothelial glycocalyx as an additional barrier determining extravasation of 6% hydroxyethyl starch or 5% albumin solutions in the coronary vascular bed. Anesthesiology 100 (2004) 1211-1223
9. Lang K., Boldt J., Suttner S., and Haisch G. Colloids versus crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery. Anesthesia and Analgesia 93 (2001) 405-409
10. Boldt J., Ducke M., Kumle B., et al. Influence of different volume replacement strategies on inflammation and endothelial activation in the elderly undergoing major abdominal surgery. Intensive Care Medicine 30 (2004) 416-422
11. Boldt J. Pro: use of colloids in cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia 21 (2007) 453-456
12. Chalidis B., Kanakaris N., and Giannoudis P.V. Safety and efficacy of albumin administration in trauma. Expert Opinion on Drug Safety 6 (2007) 407-415
13. Wong F. Drug insight: the role of albumin in the management of chronic liver disease. Nature Clinical Practice. Gastroenterology & Hepatology 4 (2007) 43-51
14. Liberati A., Moja L., Moschetti I., et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Internal and Emergency Medicine 1 (2006) 243-245
15. Mendez C.M., McClain C.J., and Marsano L.S. Albumin therapy in clinical practice. Nutrition in Clinical Practice 20 (2005) 314-320
16. Alderson P., Bunn F., Lefebvre C., et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database of Systematic Reviews (Online) 4 (2004) CD001208
17. Bayliss W.M. Intravenous injection in wound shock. British Medical Journal 1 (1918) 553
18. Le Gal Y.M. A review of the history of blood replacement from the 17th to the 20th centuries. Review of Surgery 32 (1975) 229-239
19. Hogan J.J. The intravenous use of colloidal (gelatin) solutions in shock. The Journal of the American Medical Association 64 (1915) 721
20. Hecht G., and Weese H. Periston, ein neuer Blutflüssigkeitsersatz. MMW, Münchener Medizinische Wochenschrift 90 (1943) 11
21. Wesse H., and Scholtan W. Pharmacology of periston N. Deutsche Medizinische Wochenschrift (1946) 76 (1951) 1492-1493
22. Grönwall A., and Ingelman B. Untersuchungen über Dextran und sein Verhalten bei parenteraler Zufuhr. I. Chemische und physikalisch-chemische Untersuchungen über Dextran. Acta Physiologica Scandinavica 7 (1944) 97-107
23. Aktories K. General and specific pharmacology and toxicology. 9th edn. (2006), Elsevier, Urban & Fischer, Munich
24. Koekenberg L.J. Experimental use of macrodex as a prophylaxis against post-operative thrombo-embolism. Bulletin de la Société Internationale de Chirurgie 21 (1962) 501-512
25. Gruber U.F. Prevention of fatal postoperative pulmonary embolism by heparin dihydroergotamine or dextran 70. The British Journal of Surgery 69 Suppl. (1982) S54-S58
26. Gruber U.F., Saldeen T., Brokop T., et al. Incidences of fatal postoperative pulmonary embolism after prophylaxis with dextran 70 and low-dose heparin: an international multicentre study. British Medical Journal 280 (1980) 69-72
27. Hohl M.K., Luscher K.P., Tichy J., et al. Prevention of postoperative thromboembolism by dextran 70 or low-dose heparin. Obstetrics and Gynecology 55 (1980) 497-500
28. Kamler M., Pizanis N., Hagl S., et al. Extracorporal-circulation-induced leukocyte/endothelial cell interaction is inhibited by dextran. Clinical Hemorheology and Microcirculation 31 (2004) 139-148
29. Ljungstrom K.G. The antithrombotic efficacy of dextran. Acta Chirurgica Scandinavica. Supplementum 543 (1988) 26-30
30. Bronwell A.W., Artz C.P., and Sako Y. Evaluation of blood loss from a standardized wound after dextran. Surgical Forum 5 (1955) 809-814
31. Kruger K., Seifart W., and Freudenberg R. Infusion incidents with dextran. Acta Anaesthesiologica 13 (1988) 259-271
32. Schortgen F., Girou E., Deye N., and Brochard L. The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Medicine 34 (2008) 2157-2168
33. Godwin G. Dextrans and compatibility testing. Transfusion 27 (1987) 366-367
34. Schortgen F., Deye N., and Brochard L. Preferred plasma volume expanders for critically ill patients: results of an international survey. Intensive Care Medicine 30 (2004) 2222-2229
35. Hussain S.F., and Drew P.J. Acute renal failure after infusion of gelatins. British Medical Journal 299 (1989) 1137-1138
36. Wiedersheim M. An investigation of oxyethylstarch as a new plasma volume expander in animals. Archives Internationales de Pharmacodynamie et de Thérapie 111 (1957) 353-361
37. Mishler J.M. Pharmacology of hydroxyethyl starch - use in therapy and blood banking (1982), Oxford University Press, New York, Toronto
38. Food and Drug Administration. FDA approves voluven to treat serious blood volume loss following surgery. Available from:. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01765.html
39. Hoffmann J.N., Vollmar B., Laschke M.W., et al. Hydroxyethyl starch (130 kD), but not crystalloid volume support, improves microcirculation during normotensive endotoxemia. Anesthesiology 97 (2002) 460-470
40. Singh N., Singh S., Kaur L., et al. Morphological, thermal and rheological properties of starches from different botanical sources. Food Chemistry 81 (2003) 219-231
41. Sommermeyer R., Cech F., and Schossow R. Differences in chemical structures between waxy maize- and potato-starch-based hydroxyethyl starch volume therapeutics. Transfusion Alternatives in Transfusion Medicine 9 (2007) 127-133
42. Godet M.C., Tran V., Colonna P., and Buleon A. Inclusion/exclusion of fatty acids in amylose complexes as a function of the fatty acid chain length. International Journal of Biological Macromolecules 17 (1995) 405-408
43. Szejtli J., and Bánky-Elöd I. Determination of dissociation-constants of amylose clathrates. Stärke 30 (1978) 85-91
44. Jungheinrich C., Scharpf R., Wargenau M., et al. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment. Anesthesia and Analgesia 95 (2002) 544-551
45. Yacobi A., Stoll R.G., Sum C.Y., et al. Pharmacokinetics of hydroxyethyl starch in normal subjects. Journal of Clinical Pharmacology 22 (1982) 206-212
46. Treib J., Haass A., Pindur G., et al. HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thrombosis and Haemostasis 74 (1995) 1452-1456
47. Treib J., Haass A., Pindur G., et al. Influence of intravascular molecular weight of hydroxyethyl starch on platelets. European Journal of Haematology 56 (1996) 168-172
48. Neff T.A., Doelberg M., Jungheinrich C., et al. Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesthesia and Analgesia 96 (2003) 1453-1459
49. Stander S., Szepfalusi Z., Bohle B., et al. Differential storage of hydroxyethyl starch (HES) in the skin: an immunoelectron-microscopical long-term study. Cell and Tissue Research 304 (2001) 261-269
50. Waitzinger J., Bepperling F., Pabst G., and Opitz J. Hydroxyethyl starch (HES) [130/0.4], a new HES specification: pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers. Drugs in R&D 4 (2003) 149-157
51. Sirtl C., Laubenthal H., Zumtobel V., et al. Tissue deposits of hydroxyethyl starch (HES): dose-dependent and time-related. British Journal of Anaesthesia 82 (1999) 510-515
52. Murphy M., Carmichael A.J., Lawler P.G., et al. The incidence of hydroxyethyl starch-associated pruritus. The British Journal of Dermatology 144 (2001) 973-976
53. Klemm E., Bepperling F., Burschka M.A., and Mosges R. Hemodilution therapy with hydroxyethyl starch solution (130/0.4) in unilateral idiopathic sudden sensorineural hearing loss: a dose-finding, double-blind, placebo-controlled, international multicenter trial with 210 patients. Otology & Neurotology 28 (2007) 157-170
54. Rudolf J. Hydroxyethyl starch for hypervolemic hemodilution in patients with acute ischemic stroke: a randomized, placebo-controlled phase II safety study. Cerebrovascular Diseases (Basel, Switzerland) 14 (2002) 33-41
55. Ring J., and Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1 (1977) 466-469
56. Laxenaire M.C., Charpentier C., and Feldman L. Anaphylactoid reactions to colloid plasma substitutes: incidence, risk factors, mechanisms. A French multicenter prospective study. Annales Françaises D'anesthèsie et de Rèanimation 13 (1994) 301-310
57. Davidson I.J. Renal impact of fluid management with colloids: a comparative review. European Journal of Anaesthesiology 23 (2006) 721-738
58. Boldt J., and Priebe H.J. Intravascular volume replacement therapy with synthetic colloids: is there an influence on renal function?. Anesthesia and Analgesia 96 (2003) 376-382
59. Schortgen F., Lacherade J.C., Bruneel F., et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 357 (2001) 911-916
60. Boldt J., Brenner T., Lehmann A., et al. Influence of two different volume replacement regimens on renal function in elderly patients undergoing cardiac surgery: comparison of a new starch preparation with gelatin. Intensive Care Medicine 29 (2003) 763-769
61. Brunkhorst F.M., Engel C., Bloos F., et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. The New England Journal of Medicine 358 (2008) 125-139
62. Moran M., and Kapsner C. Acute renal failure associated with elevated plasma oncotic pressure. The New England Journal of Medicine 317 (1987) 150-153
63. Boldt J. Hydroxyethylstarch as a risk factor for acute renal failure in severe sepsis. Lancet 358 (2001) 581-583
64. Thomas G., Balk E.M., and Jaber B.L. Effect of intensive insulin therapy and pentastarch resuscitation on acute kidney injury in severe sepsis. American Journal of Kidney Diseases 52 (2008) 13-17
65. Matheson N.A., and Diomi P. Renal failure after the administration of dextran 40. Surgery, Gynecology & Obstetrics 131 (1970) 661-668
66. Mailloux L., Swartz C.D., Capizzi R., et al. Acute renal failure after administration of low-molecular weight dextran. The New England Journal of Medicine 277 (1967) 1113-1118
67. Morgan T., and Little J.M. Renal failure and low-molecular-weight dextran. British Medical Journal 1 (1967) 635
68. Vogt N., Brinkmann A., and Georgieff M. The effect of HES, dextran and gelatin on kidney function. Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie 33 (1998) 268-270
69. Dickenmann M., Oettl T., and Mihatsch M.J. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. American Journal of Kidney Diseases 51 (2008) 491-503
70. Legendre C., Thervet E., Page B., et al. Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 342 (1993) 248-249
71. Eisenbach C., Schonfeld A.H., Vogt N., et al. Pharmacodynamics and organ storage of hydroxyethyl starch in acute hemodilution in pigs: influence of molecular weight and degree of substitution. Intensive Care Medicine 33 (2007) 1637-1644
72. Vogt N.H., Bothner U., Lerch G., et al. Large-dose administration of 6% hydroxyethyl starch 200/0.5 total hip arthroplasty: plasma homeostasis, hemostasis, and renal function compared to use of 5% human albumin. Anesthesia and Analgesia 83 (1996) 262-268
73. Sakr Y., Payen D., Reinhart K., et al. Effects of hydroxyethyl starch administration on renal function in critically ill patients. British Journal of Anaesthesia 98 (2007) 216-224
74. Ertmer C., Pinto B.B., Rehberg S., et al. Incidence of renal replacement therapy in intensive care patients treated with different hydroxyethyl starch solutions. Intensive Care Medicine 34 Suppl. 1 (2008) S196
75. Boldt J., Brosch C., Rohm K., et al. Comparison of the effects of gelatin and a modern hydroxyethyl starch solution on renal function and inflammatory response in elderly cardiac surgery patients. British Journal of Anaesthesia 100 (2008) 457-464
76. Perel P., and Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database of Systematic Reviews (Online) 4 (2007) CD000567
77. Bunn F., Trivedi D., and Ashraf S. Colloid solutions for fluid resuscitation. Cochrane Database of Systematic Reviews (Online) 1 (2008) CD001319
78. Karanko M.S. Effects of three colloid solutions on plasma volume and hemodynamics after coronary bypass surgery. Critical Care Medicine 15 (1987) 1015-1022
79. Tollofsrud S., Svennevig J.L., Breivik H., et al. Fluid balance and pulmonary functions during and after coronary artery bypass surgery: Ringer's acetate compared with dextran, polygeline, or albumin. Acta Anaesthesiologica Scandinavica 39 (1995) 671-677
80. Hiippala S., Linko K., Myllyla G., et al. Replacement of major surgical blood loss by hypo-oncotic or conventional plasma substitutes. Acta Anaesthesiologica Scandinavica 39 (1995) 228-235
81. Charlet P., Zerr C., Robert D., et al. Comparative trials of fluid gelatins on hemostasis in heart surgery in adults. Cahiers D'anesthésiologie 39 (1991) 233-238
82. Beards S.C., Watt T., Edwards J.D., et al. Comparison of the hemodynamic and oxygen transport responses to modified fluid gelatin and hetastarch in critically ill patients: a prospective, randomized trial. Critical Care Medicine 22 (1994) 600-605
83. Boldt J., Knothe C., Zickmann B., et al. Influence of different intravascular volume therapies on platelet function in patients undergoing cardiopulmonary bypass. Anesthesia and Analgesia 76 (1993) 1185-1190
84. Asfar P., Kerkeni N., Labadie F., et al. Assessment of hemodynamic and gastric mucosal acidosis with modified fluid versus 6% hydroxyethyl starch: a prospective, randomized study. Intensive Care Medicine 26 (2000) 1282-1287
85. Molnar Z., Mikor A., Leiner T., and Szakmany T. Fluid resuscitation with colloids of different molecular weight in septic shock. Intensive Care Medicine 30 (2004) 1356-1360
86. Allison K.P., Gosling P., Jones S., et al. Randomized trial of hydroxyethyl starch versus gelatine for trauma resuscitation. The Journal of Trauma 47 (1999) 1114-1121
87. Beyer R., Harmening U., Rittmeyer O., et al. Use of modified fluid gelatin and hydroxyethyl starch for colloidal volume replacement in major orthopaedic surgery. British Journal of Anaesthesia 78 (1997) 44-50
88. Huttner I., Boldt J., Haisch G., et al. Influence of different colloids on molecular markers of haemostasis and platelet function in patients undergoing major abdominal surgery. British Journal of Anaesthesia 85 (2000) 417-423
89. Kumle B., Boldt J., Piper S., et al. The influence of different intravascular volume replacement regimens on renal function in the elderly. Anesthesia and Analgesia 89 (1999) 1124-1130
90. Niemi T.T., Suojaranta-Ylinen R.T., Kukkonen S.I., and Kuitunen A.H. Gelatin and hydroxyethyl starch, but not albumin, impair hemostasis after cardiac surgery. Anesthesia and Analgesia 102 (2006) 998-1006
91. Van der Linden P.J., De Hert S.G., Daper A., et al. 3.5% urea-linked gelatin is as effective as 6% HES 200/0.5 for volume management in cardiac surgery patients. Canadian Journal of Anaesthesia 51 (2004) 236-241
92. Verheij J., van Lingen A., Raijmakers P.G., et al. Effect of fluid loading with saline or colloids on pulmonary permeability, oedema and lung injury score after cardiac and major vascular surgery. British Journal of Anaesthesia 96 (2006) 21-30
93. Haisch G., Boldt J., Krebs C., et al. Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients. Journal of Cardiothoracic and Vascular Anesthesia 15 (2001) 316-321
94. Haisch G., Boldt J., Krebs C., et al. The influence of intravascular volume therapy with a new hydroxyethyl starch preparation (6% HES 130/0.4) on coagulation in patients undergoing major abdominal surgery. Anesthesia and Analgesia 92 (2001) 565-571
95. Van der Linden P.J., De Hert S.G., Deraedt D., et al. Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for volume expansion in cardiac surgery patients: the effects on perioperative bleeding and transfusion needs. Anesthesia and Analgesia 101 (2005) 629-634
96. Boldt J., Zickmann B., Rapin J., et al. Influence of volume replacement with different HES-solutions on microcirculatory blood flow in cardiac surgery. Acta Anaesthesiologica Scandinavica 38 (1994) 432-438
97. Gan T.J., Bennett-Guerrero E., Phillips-Bute B., et al. Hextend, a physiologically balanced plasma expander for large volume use in major surgery: a randomized phase III clinical trial. Hextend study group. Anesthesia and Analgesia 88 (1999) 992-998
98. Boldt J., Haisch G., Suttner S., et al. Effects of a new modified, balanced hydroxyethyl starch preparation (Hextend) on measures of coagulation. British Journal of Anaesthesia 89 (2002) 722-728
99. Langeron O., Doelberg M., Ang E.T., et al. Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesthesia and Analgesia 92 (2001) 855-862
100. Gallandat Huet R.C., Siemons A.W., Baus D., et al. A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery. Canadian Journal of Anaesthesia 47 (2000) 1207-1215
101. Boldt J., Lehmann A., Rompert R., et al. Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopulmonary bypass. Journal of Cardiothoracic and Vascular Anesthesia 14 (2000) 264-268
102. Boldt J., Schollhorn T., Munchbach J., and Pabsdorf M. A total balanced volume replacement strategy using a new balanced hydoxyethyl starch preparation (6% HES 130/0.42) in patients undergoing major abdominal surgery. European Journal of Anaesthesiology 24 (2007) 267-275
103. Kozek-Langenecker S.A., Jungheinrich C., Sauermann W., and Van der Linden P. The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. Anesthesia and Analgesia 107 (2008) 382-390
104. Boldt J., Brosch C., Ducke M., et al. Influence of volume therapy with a modern hydroxyethylstarch preparation on kidney function in cardiac surgery patients with compromised renal function: a comparison with human albumin. Critical Care Medicine 35 (2007) 2740-2746
105. Wilkes N.J., Woolf R.L., Powanda M.C., et al. Hydroxyethyl starch in balanced electrolyte solution (Hextend) - pharmacokinetic and pharmacodynamic profiles in healthy volunteers. Anesthesia and Analgesia 94 (2002) 538-544
106. Jungheinrich C., and Neff T.A. Pharmacokinetics of hydroxyethyl starch. Clinical Pharmacokinetics 44 (2005) 681-699
107. Boldt J. Volume therapy in cardiac surgery: does the kind of fluid matter?. Journal of Cardiothoracic and Vascular Anesthesia 13 (1999) 752-763
108. Boldt J. Volume replacement therapy (2001), Georg Thieme, Stuttgart
109. Tonnessen T., Tollofsrud S., Kongsgaard U.E., and Noddeland H. Colloid osmotic pressure of plasma replacement fluids. Acta Anaesthesiologica Scandinavica 37 (1993) 424-426